|
ENTPD7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.32839999689961E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.9930999994866E-07 |
| Normal-vs-Stage2 |
2.70429999948973E-07 |
| Normal-vs-Stage3 |
5.171900E-04 |
| Normal-vs-Stage4 |
4.59389999996063E-06 |
| Stage1-vs-Stage2 |
2.991600E-01 |
| Stage1-vs-Stage3 |
8.734600E-01 |
| Stage1-vs-Stage4 |
4.067400E-01 |
| Stage2-vs-Stage3 |
4.242600E-01 |
| Stage2-vs-Stage4 |
9.895600E-01 |
| Stage3-vs-Stage4 |
4.800400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.7978000002108E-07 |
| Normal-vs-AfricanAmerican |
4.921300E-03 |
| Normal-vs-Asian |
1.62719999996508E-06 |
| Caucasian-vs-AfricanAmerican |
8.642000E-01 |
| Caucasian-vs-Asian |
3.251000E-01 |
| AfricanAmerican-vs-Asian |
4.263000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.57310000026278E-07 |
| Normal-vs-Female |
4.22710000003157E-07 |
| Male-vs-Female |
2.970200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.86650000003164E-06 |
| Normal-vs-Age(41-60Yrs) |
1.23390000439372E-08 |
| Normal-vs-Age(61-80Yrs) |
7.968200E-04 |
| Normal-vs-Age(81-100Yrs) |
1.218840E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.427610E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.680800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.924400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.639400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.164000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.486000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.245000E-01 |
| Classical-VS-Follicular |
1.598190E-02 |
| Classical-VS-Other |
1.780410E-01 |
| Classical-VS-Normal |
4.77229999995554E-06 |
| Tall-VS-Follicular |
3.969400E-01 |
| Tall-VS-Other |
2.402400E-01 |
| Tall-VS-Normal |
1.695150E-01 |
| Follicular-VS-Other |
4.634000E-01 |
| Follicular-VS-Normal |
3.71480002314684E-09 |
| Other-VS-Normal |
1.157680E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.3019997019702E-10 |
| Normal-vs-N1 |
1.90622999999279E-05 |
| N0-vs-N1 |
5.572200E-01 |
|
|
